AstraZeneca Pharma Fair Value
AstraZeneca Pharma (ASTRAZEN) average fair value is ₹1785.95 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹8648.0 (-79.35%), fair value range ₹201.8–₹4042.5. Also explore ASTRAZEN stock price history to track price trends across different timeframes.
Fair Value Analysis Export
ASTRAZEN Fair Value vs Current Price — Valuation Summary
ASTRAZEN average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). See ASTRAZEN P/B ratio history to compare market price against book value per share.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
ASTRAZEN Fair Value Analysis — Data Sources & Coverage
AstraZeneca Pharma financial data sources, valuation methods applied and sector benchmarks used — 2025 financial year. For live price and a broader fundamental view, visit ASTRAZEN share price.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the previous year (2025).
ASTRAZEN vs Healthcare Sector Peers — P/E, P/B & Market Cap
AstraZeneca Pharma P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Jeena Sikho Lifecare | JSLL | 40.02 | 22.33 | ₹7,891 |
| Accretion Pharmaceuticals | ACCPL | 13.72 | 2.43 | ₹131 |
| Par Drugs & Chemical | PAR | 8.67 | 1.01 | ₹111 |
| Auro Laboratories | AUROLAB | 91.49 | 3.91 | ₹165 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.